Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of
cancer screening and diagnostic tests, announced today the company
will present six abstracts on strategies and advancements for
improving colorectal cancer screening rates and outcomes during
Digestive Disease Week® (DDW) 2024, May 18-21 in Washington, D.C.
This includes data on Cologuard®, the best-in-class non-invasive
screening test for colorectal cancer in patients 45 and older at
average risk, and the next-generation Cologuard test in
development, Cologuard Plus™. Further details can be found at
ddw.org.
“At Exact Sciences, we know colorectal cancer screening must be
able to find and also help prevent the disease to positively impact
patient outcomes, which is how the Cologuard test was designed,”
said Paul Limburg, MD, MPH, AGAF, chief medical officer for
screening, Exact Sciences. “In addition to effective detection
rates for cancers, pre-cancers and low false positive rates,
patients need options that are convenient and easy to use. Up to
40% of the screening-eligible population in the U.S. currently
needs to be screened for colorectal cancer and our data at DDW can
inform strategies to meaningfully address this critical gap.”1
The following abstracts from Exact Sciences have been accepted
for presentation at the annual meeting:
Session Type: Research Forum Session Title:
Colorectal Cancer Screening and Surveillance: Cohort, Clinical
Outcomes & Comparative Effectiveness Studies including Trials
Session Date & Time: Saturday, May 18, from 12:30 p.m.
to 1:30 p.m. EDT Presentation Title: Comparison Of Efficient
Frontier Strategies For Guideline-endorsed Vs Non-endorsed
Colorectal Cancer Screening Tests
Session Type: Research Forum Session Title:
Colorectal Cancer Screening and Surveillance: Cohort, Clinical
Outcomes & Comparative Effectiveness Studies including Trials
Session Date & Time: Saturday, May 18, from 12:30 p.m.
to 1:30 p.m. EDT Presentation Title: Comparison Of Efficient
Frontier Strategies For Stool-based Colorectal Cancer Screening
Tests
Session Type: Research Forum Session Title:
Colorectal Cancer Screening and Surveillance: Cohort, Clinical
Outcomes & Comparative Effectiveness Studies including Trials
Session Date & Time: Saturday, May 18, from 12:30 p.m.
to 1:30 p.m. EDT Presentation Title: Estimated Average-risk
Colorectal Cancer Screening-eligible Population In The U.S.
Session Type: Research Forum Session Title:
Colorectal Cancer Screening and Surveillance: Cohort, Clinical
Outcomes & Comparative Effectiveness Studies including Trials
Session Date & Time: Saturday, May 18, from 12:30 p.m.
to 1:30 p.m. EDT Presentation Title: Eliminating The
Colonoscopy Backlog With Stool-based Colorectal Cancer Screening
Options
Session Type: Research Forum Session Title:
Cancer, Early Detection, Biomarkers for Diagnosis, Treatment and
Prognosis of GI Cancers Session Date & Time: Sunday, May
19, from 12:30 p.m. to 1:30 p.m. EDT Presentation Title:
Fecal Immunochemical Test (Fit) Performance Characteristics In
Males And Females: Should The Threshold Vary?
Session Type: Research Forum Session Title: Health
Disparities in Patients with GI Disease Session Date &
Time: Tuesday, May 21, from 12:30 p.m. to 1:30 p.m. EDT
Presentation Title: Impact Of Racial Disparities In The
Quality Of Colonoscopy Screening On Colorectal Cancer Incidence And
Mortality: A Simulation Modeling Analysis
About Cologuard
Results from Exact Sciences’ prospective, 90-site,
point-in-time, 10,000-patient pivotal trial, DeeP-C, were published
in the New England Journal of Medicine in March 2014. The Cologuard
test is included in the American Cancer Society’s (2018) colorectal
cancer screening guidelines and the recommendations of the U.S.
Preventive Services Task Force (2021) and National Comprehensive
Cancer Network (2023). The Cologuard test is indicated to screen
adults 45 years of age and older who are at average risk for
colorectal cancer by detecting certain DNA markers and blood in the
stool. Do not use the Cologuard test if you have had precancer,
have inflammatory bowel disease and certain hereditary syndromes,
or have a personal or family history of colorectal cancer. The
Cologuard test is not a replacement for colonoscopy in high-risk
patients. The Cologuard test performance in adults ages 45-49 is
estimated based on a large clinical study of patients 50 and older.
The Cologuard test performance in repeat testing has not been
evaluated.
The Cologuard test result should be interpreted with caution. A
positive test result does not confirm the presence of cancer.
Patients with a positive test result should be referred for
colonoscopy. A negative test result does not confirm the absence of
cancer. Patients with a negative test result should discuss with
their doctor when they need to be tested again. Medicare and most
major insurers cover the Cologuard test. For more information about
the Cologuard test, visit cologuard.com. Rx only.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests,
Exact Sciences gives patients and health care professionals the
clarity needed to take life-changing action earlier. Building on
the success of the Cologuard® and Oncotype® tests, Exact Sciences
is investing in its pipeline to develop innovative solutions for
use before, during, and after a cancer diagnosis. For more
information, visit ExactSciences.com, follow Exact Sciences on X
(formerly known as Twitter) @ExactSciences, or find Exact Sciences
on LinkedIn and Facebook.
NOTE: Exact Sciences and Cologuard are trademarks or registered
trademarks of Exact Sciences Corporation. All other trademarks and
service marks are the property of their respective owners.
About Digestive Disease Week
Digestive Disease Week® (DDW) is the largest international
gathering of physicians, researchers and academics in the fields of
gastroenterology, hepatology, endoscopy and gastrointestinal
surgery. Jointly sponsored by the American Association for the
Study of Liver Diseases (AASLD), the American Gastroenterological
Association (AGA), the American Society for Gastrointestinal
Endoscopy (ASGE) and the Society for Surgery of the Alimentary
Tract (SSAT), DDW is an in-person and online meeting from May
18-21, 2024. The meeting showcases more than 4,400 abstracts and
hundreds of lectures on the latest advances in GI research,
medicine and technology. More information can be found at
www.ddw.org.
Forward-Looking Statements
This news release contains forward-looking statements concerning
our expectations, anticipations, intentions, beliefs, or strategies
regarding the future. These forward-looking statements are based on
assumptions that we have made as of the date hereof and are subject
to known and unknown risks and uncertainties that could cause
actual results, conditions and events to differ materially from
those anticipated. Therefore, you should not place undue reliance
on forward-looking statements. Examples of forward-looking
statements include, among others, statements we make regarding the
development and commercialization of the next-generation Cologuard
test; the performance characteristics of next-generation Cologuard
in a commercial setting; and the timing and anticipated results of
additional analysis of the BLUE-C data and FDA submission. Risks
and uncertainties that may affect our forward-looking statements
are described in the Risk Factors sections of our most recent
Annual Report on Form 10-K and any subsequent Quarterly Reports on
Form 10-Q, and in our other reports filed with the Securities and
Exchange Commission. We undertake no obligation to publicly update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
References
- Siegel RL, et al. 2023. CA Cancer J Clin.
2023;73(3):233-254.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240507199503/en/
Media (U.S.): Lindsey Dickinson +1 608-690-0383
lidickinson@exactsciences.com Investors: Nathan Harrill +1 608
535-8659 investorrelations@exactsciences.com
EXACT Sciences (NASDAQ:EXAS)
Historical Stock Chart
From Jul 2024 to Aug 2024
EXACT Sciences (NASDAQ:EXAS)
Historical Stock Chart
From Aug 2023 to Aug 2024